P/B
2,4
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
$408.7M
Market Cap • 9/22/2026
2008
(18 years)
Founded
2013
(13 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
13,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
6,1
EPS
—
Market Cap
Market Cap
408,7M
EV
236,2M
EV/Revenue
8
EV/EBITDA
-2,4
EV/EBIT
-2,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-3,2%
Total Yield
-3,2%
Payout
0%
Retained Earnings
-565,3M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
295,5%
Capex/Revenue
0,3%
Capex/D&A
3,4%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
11,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
27,5%
CAGR Op. Income 5Y
-8,9%
CAGR Net Income 5Y
-10,6%
CAGR EPS 5Y
-12,3%
CAGR OCF 5Y
-5,9%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
5,9
Quick Ratio
5,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!